Profile data is unavailable for this security.
About the company
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.
- Revenue in USD (TTM)31.58m
- Net income in USD-116.17m
- Incorporated2012
- Employees69.00
- LocationCidara Therapeutics Inc6310 Nancy Ridge Dr Ste 101SAN DIEGO 92121-3209United StatesUSA
- Phone+1 (858) 752-6170
- Fax+1 (302) 655-5049
- Websitehttps://www.cidara.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMV Pharmaceuticals Inc | 0.00 | -48.88m | 77.79m | 63.00 | -- | 0.363 | -- | -- | -0.9662 | -0.9662 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -20.38 | -21.16 | -21.39 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -34.44m | 78.49m | 16.00 | -- | 24.19 | -- | -- | -0.934 | -0.934 | 0.00 | 0.0504 | 0.00 | -- | -- | 0.00 | -204.48 | -111.48 | -838.03 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Omega Therapeutics Inc | 6.31m | -78.90m | 78.87m | 93.00 | -- | 3.00 | -- | 12.49 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Renovaro Inc | 0.00 | -88.12m | 79.76m | 11.00 | -- | 0.473 | -- | -- | -1.08 | -1.08 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -60.56 | -27.81 | -68.21 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Bioatla Inc | 0.00 | -104.56m | 80.24m | 65.00 | -- | 2.56 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Vistagen Therapeutics Inc | 970.40k | -33.19m | 81.03m | 41.00 | -- | 0.7732 | -- | 83.50 | -1.53 | -1.53 | 0.0386 | 3.87 | 0.0151 | -- | -- | 24,882.05 | -51.63 | -62.84 | -56.12 | -68.03 | -- | -- | -3,420.44 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Cidara Therapeutics Inc | 31.58m | -116.17m | 81.78m | 69.00 | -- | 0.4055 | -- | 2.59 | -25.49 | -25.30 | 6.95 | 28.66 | 0.2617 | -- | 8.06 | 457,623.20 | -96.27 | -65.23 | -136.45 | -154.37 | 91.14 | -- | -367.91 | -100.61 | -- | -- | 0.0053 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -48.41m | 82.57m | 47.00 | -- | 2.58 | -- | -- | -1.01 | -1.01 | 0.00 | 0.6003 | 0.00 | -- | -- | 0.00 | -51.98 | -48.44 | -55.36 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6171 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 82.66m | 127.00 | -- | 1.55 | -- | 16.53 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
| Aclaris Therapeutics Inc | 32.02m | -58.68m | 83.47m | 91.00 | -- | 0.6237 | -- | 2.61 | -0.8267 | -0.8267 | 0.4509 | 1.88 | 0.1614 | -- | 84.70 | 351,824.20 | -29.58 | -47.29 | -32.76 | -53.87 | 42.63 | 44.00 | -183.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Benitec Biopharma Inc | 7.00k | -21.69m | 84.32m | 18.00 | -- | 1.98 | -- | 12,045.71 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
| Genelux Corp | 8.00k | -26.54m | 84.61m | 23.00 | -- | 2.22 | -- | 10,576.49 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 84.71m | 12.00 | -- | 8.34 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Beyondspring Inc | 1.88m | -15.57m | 86.04m | 35.00 | -- | -- | -- | 45.86 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Data as of Sep 19 2024. Currency figures normalised to Cidara Therapeutics Inc's reporting currency: US Dollar USD
29.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 19 Jul 2024 | 703.08k | 9.99% |
| Monashee Investment Management LLCas of 30 Jun 2024 | 369.10k | 5.24% |
| BVF Partners LPas of 30 Jun 2024 | 343.06k | 4.87% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 179.64k | 2.55% |
| Checkpoint Capital LPas of 30 Jun 2024 | 145.42k | 2.07% |
| Apo Asset Management GmbHas of 30 Sep 2023 | 98.13k | 1.39% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 95.52k | 1.36% |
| Alethea Capital Management LLCas of 30 Jun 2024 | 79.91k | 1.14% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 47.57k | 0.68% |
| Geode Capital Management LLCas of 30 Jun 2024 | 43.13k | 0.61% |
More ▼
Data from 30 Apr 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
